Posted: February 24, 2023 at 12:14 am
– Transformational year ahead with critical Phase 2 readouts expected for programs in hepatitis B, hepatitis D and influenza with the potential for significant patient impact –
Continue reading here:
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced anticipated registrational path
Read more here:
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Posted: February 24, 2023 at 12:14 am
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid Absorption
Read the original:
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Posted: February 24, 2023 at 12:14 am
Initiated ReSPECT-GBM Phase 2 and ReSPECT- LM Phase 1 trials for CNS cancers
See original here:
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
Posted: February 24, 2023 at 12:14 am
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications
See the rest here:
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
CHATHAM, N.J., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of R. Newcomb Stillwell to its Board of Directors, to be effective as of March 15, 2023.
Continued here:
Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell
Posted: February 24, 2023 at 12:14 am
FREMONT, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has closed a funding agreement for gross proceeds of $3.175 million (the "Investment") with Lind Global Fund II, LP, an investment fund managed by The Lind Partners (together “Investor” or “Lind”), a New York-based institutional fund manager.
Read more here:
ABVC BioPharma Receives $3.175 Million Investment From The Lind Partners to Continue Clinical Trials
Posted: February 24, 2023 at 12:14 am
— Company expects to announce data for Factor VIII expression in non-human primates in 2023
Here is the original post:
Generation Bio Outlines 2023 Strategic Priorities and Reports Fourth Quarter and Full Year 2022 Financial Results
Posted: February 24, 2023 at 12:14 am
– Initiated enrollment in Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in platinum-resistant ovarian cancer –
Excerpt from:
Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates
Posted: February 24, 2023 at 12:14 am
Combined company will be focused on advancing Enliven’s clinical-stage pipeline of precision oncology programs
View original post here:
Enliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
